Effect of alphapinen addition to quadruple therapy for the eradication of Helicobacter pylori gastrointestinal infectious

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N15

Enrollment

Registered

2023-06-21

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious with Helicobacter pylori. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Addition ofalphapinen orally 10 mg/d to eradication regimen of Helicobacter pylori for 2 weeks. Intervention 2: Control group: Addition of alphapinen placebo 1 caps

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients who infected with Helicobacter pylori on the basis of doing urease breath test Obtaining written informed consent

Exclusion criteria

Exclusion criteria: Patients with previous history of allergy to alphapinen

Design outcomes

Primary

Measure	Time frame
Eradication of Helicobacter pylori. Timepoint: 1month after finishing drugs. Method of measurement: Assesing the urease breath test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026